In 2002, the Women's Health Initiative (WHI) changed how millions of women and healthcare professionals viewed hormone replacement therapy (HRT). Headlines warned of breast cancer, heart attacks, and strokes, causing hormone therapy prescriptions to decline sharply.
More than two decades later, research and long-term follow-up have clarified what the study found, its limitations, and why the benefits and risks of hormone therapy differ among women.
The takeaway is not that hormone therapy is dangerous for everyone or risk-free. Understanding the research means looking beyond headlines and considering the type of hormones studied, a woman's age, time since menopause, health history, and treatment goals.
What happened in 2002?
The Women's Health Initiative was a large, government-funded research program designed to evaluate strategies to prevent chronic diseases in postmenopausal women.
In July 2002, researchers stopped the WHI trial studying oral conjugated equine estrogen plus medroxyprogesterone acetate, a combination used by women with a uterus. Investigators concluded the overall balance of risks and benefits did not support using that regimen to prevent chronic disease.
The findings raised concerns about breast cancer, coronary heart disease, stroke, and blood clots. Although the study included important information about the benefits and risks of the specific treatment tested, public discussion often became broader: hormone therapy was treated as if every formulation carried the same risks for every woman.
That distinction matters. The WHI provided important evidence, but its findings must be interpreted in the context of the population studied and the hormone regimens evaluated.
Myth 01
The WHI proved that all hormone therapy is dangerous
What the research found
The WHI studied specific hormone regimens, and the results differed between its two trials.
The WHI included two major hormone therapy trials:
- Estrogen plus progestin: Oral conjugated equine estrogen combined with medroxyprogesterone acetate in women with a uterus.
- Estrogen alone: Oral conjugated equine estrogen in women who had undergone a hysterectomy.
These trials produced different findings, notably about breast cancer. Their results cannot automatically be applied to every estrogen formulation, progestogen, dose, or route of administration used today.
For example, estradiol and micronized progesterone differ from the specific hormones tested in the combined WHI trial. Transdermal estrogen, delivered through a patch or gel, also differs from oral estrogen in how the body absorbs and processes it.
These differences are clinically relevant but do not prove modern formulations are risk-free. Evidence from the WHI remains important, and we must assess risks of other formulations using available evidence.
Myth 02
The risks reported in the WHI were enormous
What the research found
Relative risks and absolute risks tell different parts of the story.
The 2002 WHI trial of estrogen plus progestin reported increased rates of several outcomes. Looking at absolute numbers helps explain how large those differences are.
In the trial, the annualized rates per 10,000 women-years were approximately:
| Outcome | Placebo | Estrogen plus progestin | Difference |
|---|---|---|---|
| Invasive breast cancer | 30 | 38 | +8 |
| Coronary heart disease events | 30 | 37 | +7 |
| Stroke | 21 | 29 | +8 |
| Pulmonary embolism | 8 | 16 | +8 |
Annualized rates per 10,000 woman-years. Source: Writing Group for the Women's Health Initiative Investigators, JAMA, 2002.
These figures describe the specific regimen studied in the trial, with participants averaging approximately 63 years of age.
For example, the breast cancer result represented about eight additional cases per 10,000 woman-years in the hormone therapy group. The stroke difference was also about eight additional events per 10,000 woman-years, while the difference in coronary heart disease events was about seven.
Relative risk describes how much risk changes relative to the comparison group. Absolute risk shows the actual event rates. Both are important when evaluating treatment options.
A small absolute difference does not mean a risk is unimportant, and a large relative percentage does not mean an event is common. The right interpretation depends on the outcome, population, and treatment considered.
Myth 03
The WHI studied women just entering menopause
What the research found
The average participant was older than the typical woman seeking treatment for new menopausal symptoms.
Women in the WHI hormone trials were between 50 and 79 years old, averaging about 63. Many were more than a decade past menopause.
The trials were designed primarily to evaluate whether hormone therapy could prevent chronic diseases, including heart disease, rather than to assess treatment for hot flashes and night sweats in women beginning menopause.
This distinction helped researchers investigate whether age and the timing of hormone therapy initiation modify outcomes.
Subsequent analyses found age and time since menopause are important when evaluating benefits and risks. Women who begin therapy closer to menopause generally have a more favorable benefit-risk profile than those who begin later. However, this does not mean that starting hormone therapy early guarantees cardiovascular protection or eliminates other risks.
Myth 04
Hormone therapy causes the same breast cancer risk in every woman
What the research found
The WHI estrogen-only and combined-therapy trials produced different breast cancer findings.
In the WHI trial of estrogen alone, women with a prior hysterectomy who received conjugated equine estrogen had lower breast cancer incidence during long-term follow-up than women assigned to placebo.
By contrast, the estrogen-plus-medroxyprogesterone trial found higher breast cancer incidence during follow-up.
These results are important because they show that estrogen-only therapy and combined estrogen-progestin therapy should not be treated as interchangeable when discussing breast cancer risk.
The estrogen-only findings do not prove estrogen is universally protective against breast cancer. They apply only to the population and formulation studied and should not be generalized to every woman or estrogen product.
For women with an intact uterus who use systemic estrogen, a progestogen is generally needed to protect the uterine lining from unopposed estrogen. Treatment choice entails balancing uterine safety, breast cancer considerations, and other individual risk factors.
Myth 05
The WHI found that hormone therapy makes women die sooner
What the research found
Long-term follow-up did not find a significant difference in overall mortality between the hormone therapy and placebo groups.
A 2017 analysis published in JAMA examined 18 years of cumulative follow-up from the WHI hormone trials. It found no significant difference in all-cause mortality between women assigned to hormone therapy and those assigned to placebo.
This finding gives important context for comprehending the long-term outcomes of the trials.
However, it does not mean hormone therapy carries no risks. Mortality is only one outcome, and women may experience differences in breast cancer incidence, cardiovascular events, blood clots, fractures, and menopausal symptoms without those differences producing a detectable change in overall mortality. Treatment decisions should consider the full benefit-risk profile rather than relying on one outcome alone.
Myth 06
Modern hormone therapy has the same risk profile as every treatment studied in the WHI
What the research found
Formulation, dose, and route matter, although the evidence is not equally strong for every product.
The WHI used oral conjugated equine estrogen, with or without medroxyprogesterone acetate. Today, menopause care may involve other formulations, including estradiol and micronized progesterone, as well as transdermal estrogen.
Oral estrogen passes through the liver before reaching systemic circulation. Transdermal estrogen bypasses this liver processing and may have a lower risk of venous blood clots than oral estrogen, based largely on observational evidence.
That does not mean transdermal estrogen carries zero risk or that every route is appropriate for every patient.
Choice of hormone, dose, and route should consider the woman's symptoms, age, time since menopause, medical history, clotting and cardiovascular risk factors, breast cancer history, and uterine status.
The goal is not to assume one treatment is universally safer but to select an appropriate option based on available evidence and the patient's circumstances.
What has changed in hormone therapy guidance?
In November 2025, the FDA requested changes to boxed warnings on menopause hormone therapy products. In February 2026, the agency approved updated labeling for six products, removing boxed-warning statements related to cardiovascular disease, breast cancer, and probable dementia.
This was a change in how risks were presented in product labeling, not a declaration that hormone therapy is risk-free. Relevant safety information about cardiovascular disease and breast cancer remains in other sections of labeling, and the boxed warning for endometrial cancer remains on systemic estrogen-only products.
The updated labeling shows a more individualized approach to communicating benefits and risks, including consideration of hormone therapy for appropriate women younger than 60 or within 10 years of menopause.
Hormone therapy remains an established treatment for bothersome menopausal symptoms, including hot flashes and night sweats, and can help prevent bone loss. It is not recommended solely to prevent cardiovascular disease or dementia.
What should women take away from the WHI?
The WHI remains one of the most important sources of evidence about menopause hormone therapy. Don't dismiss its findings, but don't apply them indiscriminately to every woman and every treatment.
Here are five practical points to remember:
- Ask about absolute risks. Relative percentages can sound alarming without the underlying event rates.
- Understand which treatment was studied. Estrogen alone and estrogen combined with a progestogen have different evidence and risk profiles.
- Consider timing. Age and time since menopause influence the balance of benefits and risks.
- Discuss your personal health history. Breast cancer risk, clotting history, cardiovascular health, uterine status, and other factors affect treatment decisions.
- Reassess treatment over time. Your symptoms, health and preferences may change, so treatment should be reviewed periodically.
The most useful lesson from the WHI is that hormone therapy decisions require context. Women deserve clear information about the possible benefits, the known risks, and the limits of the available evidence.
Sources
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. Read the study.
- Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. doi:10.1001/jama.291.14.1701
- Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380. doi:10.1001/jama.2020.9482
- Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. doi:10.1001/jama.2017.11217
- Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. doi:10.1001/jama.297.13.1465
- U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026.
- U.S. Office on Women's Health. Hormone Therapy Safety.
This article is general education, not individual medical advice. See our medical disclaimer.